GSK: cervical cancer vaccine on the horizon
5/26/2004 Datamonitor Services GSK is awaiting the outcome of a Phase III trial to evaluate an anti-cervical cancer vaccine. GlaxoSmithKline's [GSK.L] four-year clinical trial of an HPV vaccine could have a significant affect on cervical cancer treatment, as HPV is a known contributory factor to the disease. However, GSK will need to consider how this product should be positioned, especially with regard to use in pediatrics, so as to maximize revenues. GSK's global Phase III PATRICIA HPV vaccine trial will involve 90 sites and approximately 13,000 young women aged 15-25 worldwide, lasting for approximately four years. HPV is associated with cervical cancer, the second most common cause of cancer in women worldwide, and the leading cause in the developing world. Furthermore, cervical cancer develops early in life, with a median age of 38 years. Although there are more than 100 different types of HPV, approximately 70% of all cervical cancers are associated with just two types, namely HPV 16 and HPV 18. It is against these oncogenic strains that the HPV vaccine is intended to confer protection. GSK's main challenge will be identifying the optimal target population. Judging by the proposed trial, it can be inferred that GSK anticipates its target population to be young women, from mid-teens to early twenties. This means that the HPV vaccine will not be included on the US pediatric immunization schedule, which is the most commercially attractive sector for vaccine manufacturers due to its large patient population and high compliance rates. Consequently, GSK will [...]